Canada approves GSK's RSV vaccine for adults aged 50 to 59
Nov 5 (Reuters) -GSK GSK.L has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group.
The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration approving it for that age group.
Arexvy is already approved in the United States and the European Union for use in adults between 50 and 59. It was previously approved only for those 60 and older in Canada, as is Pfizer's PFE.N RSV vaccine, Abrysvo.
RSV, which typically causes cold-like symptoms, is a leading cause of pneumonia in toddlers and older adults.
Hospitalizations associated with RSV in adults start to increase at the age of 50, GSK's interim Canada medical director, Michelle Horn, said.
Among Canadian adults 50 and older who are hospitalized with RSV, about 98% have at least one chronic condition, according to GSK.
The company has also filed regulatory submissions for the approval of Arexvy in adults aged 50 to 59 in Japan and other countries.
It expects to release data from two studies of the vaccine in adults 18 and above later in 2024.
Reporting by Puyaan Singh in Bengaluru; Editing by Pooja Desai
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
